摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin | 5627-31-6

中文名称
——
中文别名
——
英文名称
1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin
英文别名
1,4,9-Triaza-bicyclo<5.3.0>dec-9-en;2,3,5,6,7,8-hexahydro-1H-imidazo[1,2-a][1,3]diazepine;2,3,5,6,7,8-Hexahydro-1H-imidazo[1,2-a][1,3]diazepin;3H-Imidazo[1,2-a]-1,3-diazepine, 1,2,5,6,7,8-hexahydro-;2,3,5,6,7,8-hexahydro-1H-imidazo[1,2-a][1,3]diazepine
1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin化学式
CAS
5627-31-6
化学式
C7H13N3
mdl
MFCD19227991
分子量
139.2
InChiKey
HBWDWJSRXYGILY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    222.3±23.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    27.6
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:8c1d4a790e0dbdb1317b0180dda3dc6d
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    PREPARATION AND CHEMISTRY OF Δ8-HEXAHYDRO-1,4,8-PYRIMIDAZOLE, Δ9-1,5,9-TRIAZABICYCLO(4.4.0)DECENE, AND Δ9-1,4,9-TRIAZABICYGLO(5.3.0)DECENE
    摘要:
    Δ8-六氢-1,4,8-嘧啶,Δ9-1,5,9-三氮杂双环(4.4.0)癸烯和Δ9-1,4,9-三氮杂双环(5.3.0)癸烯的制备方法从相应的2-(ω-羟基烷基氨基)-Δ2-1,3-二氮杂环烯经氯化和脱卤反应得到。这些双环化合物的硝基衍生物在回流乙醇中比1-硝基-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑稳定。
    DOI:
    10.1139/v57-190
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 作用下, 生成 1.2.5.6.7.8-Hexahydro-3H-imidazo<1.2-a>1.3-diazepin
    参考文献:
    名称:
    PREPARATION AND CHEMISTRY OF Δ8-HEXAHYDRO-1,4,8-PYRIMIDAZOLE, Δ9-1,5,9-TRIAZABICYCLO(4.4.0)DECENE, AND Δ9-1,4,9-TRIAZABICYGLO(5.3.0)DECENE
    摘要:
    Δ8-六氢-1,4,8-嘧啶,Δ9-1,5,9-三氮杂双环(4.4.0)癸烯和Δ9-1,4,9-三氮杂双环(5.3.0)癸烯的制备方法从相应的2-(ω-羟基烷基氨基)-Δ2-1,3-二氮杂环烯经氯化和脱卤反应得到。这些双环化合物的硝基衍生物在回流乙醇中比1-硝基-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑稳定。
    DOI:
    10.1139/v57-190
点击查看最新优质反应信息

文献信息

  • SOME NEW SULPHONAMIDES AND DERIVATIVES OF BICYCLIC GUANIDINES
    作者:M.-E. Kreling、A. F. McKay
    DOI:10.1139/v58-114
    日期:1958.5.1
    The preparations and bacteriostatic activities of some sulphonamide derivatives of the bicyclic guanidines are described. Some l-(2-hydroxy-3-(aryloxy)propyl)-2,3,5,6-tetrahydro-1-imidaz(1,2-a)imidazoles have also been prepared.
    描述了一些双环磺酰胺衍生物的制备和抑菌活性。还制备了一些1-(2-羟基-3-(芳氧基)丙基)-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑
  • Strong reducing agents containing dimolybdenum Mo24+ units and their oxidized cations with Mo25+/6+ cores stabilized by bicyclic guanidinate anions with a seven-membered ring
    作者:F. Albert Cotton、Carlos A. Murillo、Xiaoping Wang、Chad C. Wilkinson
    DOI:10.1039/b608422b
    日期:——
    The syntheses of two analogues of the bicyclic guanidinate ligand hpp (hpp = the anion of the guanidine-type compound 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2a]pyrimidine) which contain two fused rings are reported. Each compound contains one seven-membered ring while the other is either a five (Htbd) or a six (Htbu) membered ring. In THF/Bu4NPF6, the dimolybdenum compounds Mo2(tbd)4 and Mo2(tbu)4 are easily oxidized and they have signals in the differential pulse voltammograms at −1.059 and −1.009 V (vs. Ag/AgCl), respectively and for the Mo25+/6+ couples and in the same order −0.242 and −0.312 V for the Mo26+/5+ couples. The two compounds produce the corresponding Mo2(bicyclic guanidinate)4Cl compounds immediately upon dissolution in CH2Cl2 and these easily form species with Mo26+ cores. In Mo2(tbd)4Cl there are two crystallographically independent molecules with Mo–Mo distances of 2.1711(7) and 2.1690(7) Å. The distance between metal atoms increases to 2.206(1) Å upon oxidation to Mo2(tbd)4Cl2 which has a triply bonded Mo26+ core. For the diamagnetic compound Mo2(tbu)4 this distance is 2.0677(9) Å and it increases to 2.133(2) Å upon reduction of the bond order from 4 to 3.5 in the paramagnetic compound Mo2(tbu)4Cl.
    报告了两种含有两个稠环的二环配体hpp(hpp = 基化合物1,3,4,6,7,8-六氢-2H-嘧啶并[1,2a]嘧啶的阴离子)类似物的合成。每种化合物包含一个七元环,而另一个要么是五元环(Htbd),要么是六元环(Htbu)。在THF/Bu4NPF6中,二化合物Mo2(tbd)4和Mo2(tbu)4很容易被氧化,它们在差分脉冲伏安图中的信号分别为-1.059和-1.009 V(相对于Ag/AgCl),对于Mo25+/6+偶合,信号顺序为-0.242和-0.312 V,对于Mo26+/5+偶合,信号顺序为-0.242和-0.312 V。这两种化合物在溶于CH2Cl2后立即产生相应的Mo2(二环基)4Cl化合物,这些化合物很容易形成具有Mo26+核心的物种。在Mo2(tbd)4Cl中,有两个晶体学上独立的分子,Mo-Mo距离分别为2.1711(7)和2.
  • Procédé de synthèse d'esters de l'acide mercapto-3 propionique
    申请人:ELF AQUITAINE EXPLORATION PRODUCTION FRANCE
    公开号:EP0844237B1
    公开(公告)日:2000-05-31
  • SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD
    申请人:Lubrizol Advanced Materials, Inc.
    公开号:EP3065831A1
    公开(公告)日:2016-09-14
  • Semi-Permanent Hair Straightening Composition And Method
    申请人:LUBRIZOL ADVANCED MATERIALS, INC.
    公开号:US20160296449A1
    公开(公告)日:2016-10-13
    A composition and a process for straightening hair are disclosed. The process includes coating keratin fibers with a composition comprising a thermally-activated agent and a guanidine moiety containing adjuvant compound and contacting the coated keratin fibers with a heating device at a temperature of at least 185 C for sufficient time to modify the keratin fibers.
查看更多

同类化合物

脱氧助间型霉素 叔-丁基3-溴-8,9-二氢-5H-咪唑并[1,2-D][1,4]二氮杂卓-7(6H)-甲酸基酯 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 9H-imidazo[2,1-i]purin-8-one 3-(2-chlorobenzyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one R-(-)-7-Methyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,64-icosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate tert-butyl (1-(1-(but-2-yn-1-yl)-4-methyl-7-oxo-6,7-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl)piperidin-3-yl)carbamate 14-(7-(bromomethyl)-1H-imidazo[4,5-c]pyridin-4-yl)-14-azadispiro[5.0.57.36]pentadecane-13,15-dione cyclo-(-ImPyPyPy-(R)β-NHCbzγ-ImPyPyPy-(R)β-NHCbzγ-) benzyl N-[(23R,52R)-23-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-52-yl]carbamate 2-tert-butyldimethylsilyl-5-[(1S,2S)-2-dibenzylamino-1,4-dihydroxybutyl]-N,N-dimethylimidazole-1-sulfonamide 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate (8R)-3-(p-Methoxybenzyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 8H-Pyrazino[1,2-a]pyrimidine-8-carboxylic acid, 2-(2-aminoethyl)-4,6,7,9-tetrahydro-4-oxo-, 1,1-dimethylethyl ester 3,4,6,7-Tetrahydro-7-methyl-4-propylimidazo[4,5-e][1,4]diazepine-5,8-dione 1-methyl-1,2,3,4-tetrahydropyrido<3',2':4,5>imidazo<1,2-a>pyrimidin-2-one 5-(4H-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine hydrobromide tert-butyl 7-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridine-2(1H)-carboxylate N-(7H-Imidazo<1,5c><1,3>diazepin-5(6H)-yliden)-N'-<2-<(5-methyl-1H-imidazol-4-yl)methylthio>ethyl>harnstoff 1,2-Dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-e][1,4]diazepin-8-one 1-benzyl-5-hydroxy-4,5,6,7-tetrahydroimidazo<4,5-e><1,4>diazepin-8(1H)-one [5-(8-Hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-pentyl]-phosphonic acid dibenzyl ester 6,7-dihydro-3-<(2-hydroxyethoxy)methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid monohydrochloride 1,6-dimethyl-1,4,6,7-tetrahydro-imidazo[4,5-b]pyridin-5-one 1-Benzyl-7,8-dihydro-1H,5H-imidazo<4,5-e><1,3>diazepine-4,6-dione methyl5H,6H,7H,8H,9H-imidazo[1,2-a][1,4]diazepine-6-carboxylatedihydrochloride 3-(2,4-difluorophenyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one 3-(3,5-dimethyl-cyclohexyl)-1-methyl-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 3-{5-[2-(2-Trimethylsilanyl-ethoxymethyl)-2H-tetrazol-5-yl]-pentyl}-3,6,7,8-tetrahydro-imidazo[4,5-d][1,3]diazepin-8-ol N-{4-[(8-cyclohexyl-2,8-diazaspiro[4.5]dec-2-yl)methyl]benzyl}-2-(1H-imidazol-4-yl)-N-(1H-imidazol-2-ylmethyl)ethanamine 4-Fluoro-3-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester (8S)-3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-5-methylimidazo<4,5-d><1,3>diazepin-8-ol 6,7-dihydro-3-<<2-(p-toluoyloxy)ethoxy>methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 3,4-dibenzyl-4,5,7,8-tetrahydro-6-hydroxy-6H-imidazo[4,5-e][1,4]diazepine-5,8-dione